Mary Mulcahy, MD
Medical Oncology · Chicago, ILNPI 1306870837
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 94.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $7,250 and has fallen 97.7% since, to $165 in 2025.
Across 10 payments — averaging $768.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$7K
- Biocompatibles, Inc.$168
- Intera Oncology, Inc$86
- Ipsen Biopharmaceuticals, Inc$79
- Foundation Medicine, Inc.$41
- Astellas Pharma US Inc$35
- plus $30 from 2 others
Across 55 payments — averaging $15,739 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$244K
- Boston Scientific$232K
- Seagen Inc.$185K
- Genentech, Inc.$78K
- Biocompatibles UK Ltd$40K
- Amgen$40K
- plus $48K from 2 others
What the payments were for
- Consulting fees$4,00052%
- Speaking & faculty fees$3,25042%
- Food & beverage$3605%
- Education$791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $7,250 |
| Biocompatibles, Inc. | 1 | $168 |
| Intera Oncology, Inc | 1 | $86 |
| Ipsen Biopharmaceuticals, Inc | 1 | $79 |
| Foundation Medicine, Inc. | 1 | $41 |
| Astellas Pharma US Inc | 1 | $35 |
| Tempus AI, Inc | 1 | $18 |
| Bio Products Laboratory USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL PAIN MANAGEMENT$7,250
- THERASPHERE-BIO$168
How this compares
$7,689 in reported general payments places this provider in the 75th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 32 | $75,583 |
| Imatinib Mesylate | 11 | $31,466 |
| EliquisApixaban | 39 | $24,727 |
| Ondansetron OdtOndansetron | 31 | $413 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $407 |
| Prochlorperazine Maleate | 41 | $310 |
| Ondansetron Hcl | 21 | $181 |
| Gabapentin | 15 | $150 |
| Omeprazole | 13 | $104 |
| Pantoprazole Sodium | 14 | $75 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Chicago
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
- Jyoti PatelChicago$175K
- Al BensonChicago$163K
- Nisha MohindraChicago$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.